Abstract:

Commercialization of nanotechnologies in Russian Health Care System (RHCS) requires detailed analysis of existing obstacles to technology translation.  Here we will discuss three key innovations (i)  Prof. Ilizarov’s apparatus, (ii) ‘Perftorun’,  known as ‘blue blood’  therapy of Russian prof. Beloyartsev, (iii) ‘Litar’ and artificial bone technology invented by Prof. Krasnov which is used to replace bones defects. We will consider challenges of Russian bionanotechnology clusters and education of scientists concerning the principles of technology transfer. Prof.  Petrov, a coauthor of this paper, has extensive experience in implementation of novel technologies for health protection and safety.  Historic data and case studies suggest that Russia’s technology innovations require 30 - 40 years before it is successfully commercialization compared to 5 to 10 years in the United States. Substantial investment capital significant and high probability of technology failure in preclinical or clinical trials hinder commercialization of biomedical and health technologies in developed countries.  Stringent regulatory approval process further increases the time and cost of moving the technology from laboratory into commercialization. Patent protection of new inventions is a key strategy for attracting substantial investment required for early stage transition of biomedical technologies into commercial products. Following the discussion of the three innovations mentioned above, our paper will suggest approaches of how to enhance commercial translation.